Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Mindset Pharma Receives Patent Allowance Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
“Family 2 has a potentially superior in-clinic macrodose profile to psilocybin. This notice of allowance reaffirms the strength of Mindset’s IP position and facilitates our ongoing development of Family 2, a highly differentiated asset in our mission to help patients with unmet needs via the discovery of optimized psychedelic medications,” said James Lanthier, CEO of Mindset Pharma. “Our Family 2 compounds have shown positive results thus far and we are looking forward to continuing our work with Otsuka to get closer to bringing Family 2 to clinical trials.”
Filament Health Announces First Dosing in FDA-Approved Clinical Trial
The phase one clinical trial, conducted at the University of California, San Francisco’s Translational Psychedelic Research Program (TrPR) under the supervision of Dr. Joshua Woolley, is the first to directly administer psilocin and psilocybin derived from mushrooms, as opposed to lab-created synthetic substances.
“We are excited to conduct the first trial of naturally sourced psilocybin and the first modern trial of psilocin from any source,” said Dr. Joshua Woolley, MD/Ph.D., director of TrPR and the study’s Principal Investigator. “This trial will provide crucial information about the effects and mechanisms of these compounds that could allow for greatly enhanced psychedelic-assisted therapy.”
Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
CLARITY is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of 25 mg synthetic psilocybin in conjunction with Motivational Enhancement Therapy (MET). CLARITY has been approved in Canada and has been submitted for regulatory approval in the EU countries selected for its Phase 2 clinical trial.
“We are delighted to initiate our Phase 2 clinical trial,” said Damian Kettlewell, co-founder and CEO of Clairvoyant. “At Clairvoyant, it is our hope that the results of this clinical trial will support the company’s novel psychedelic treatment model for addressing the significant unmet medical need for AUD patients.”
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs
Nirvana Life Sciences Inc. has recently added a novel delivery system for active pharmaceutical ingredients (APIs) with high bioavailability and rapid onset to its portfolio. This novel delivery system will be used as a formulating agent for both water soluble and non-water-soluble APIs, whose onset when taken orally would be a standard twenty to forty-five minutes. This delivery system will allow the compound to bypass first pass liver metabolism and directly enter the bloodstream, resulting in a rapid onset of 5 minutes or less. This delivery system also functions as a solubilizing agent for non-water-soluble materials.
ATAI Files For Potential $300M Capital Raise
“This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a “shelf” registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $300,000,000 as described in this prospectus.”